Chronic graft-versus-host disease: clinical manifestation and therapy.
about
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosisThoracic air-leak syndromes in hematopoietic stem cell transplant recipients with graft-versus-host disease: a possible sign for poor response to treatment and poor prognosis.Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.Chronic graft-versus-host disease (GVHD) in children.Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effectsClinical-pathological conference: case 2.High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II studyFavorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantationExtracorporeal photopheresis in chronic graft-versus-host disease.Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes.Chronic graft-versus-host disease: where do we go from here?A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials.Esophageal stenosis with sloughing esophagitis: A curious manifestation of graft-vs-host diseaseChronic graft versus host disease.Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation.Mechanism of action of extracorporeal photochemotherapy in chronic graft-versus-host disease.Chronic GvHD decreases antiviral immune responses in allogeneic BMT.Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host diseaseRituximab for steroid-refractory chronic graft-versus-host disease.The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantationRecent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants.Evaluation of prognostic factors among patients with chronic graft-versus-host disease.Minimal change nephrotic syndrome after stem cell transplantation: a case report and literature review.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsA case of membranous nephropathy as a manifestation of graft-versus-host disease.Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part ILow-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.Histopathologic diagnosis of chronic graft-versus-host disease of the oral mucosa according to the National Institutes of Health Consensus.Vaccination against self to prevent autoimmune disease: the type 1 diabetes model.Large pericardial effusion as a complication in adults undergoing SCT.Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators.De novo glomerulitis associated with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A single-center experience.PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.Association of polymorphic MHC microsatellites with GVHD, survival, and leukemia relapse in unrelated hematopoietic stem cell transplant donor/recipient pairs matched at five HLA loci.Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation.
P2860
Q24673367-58C56CF9-1AD7-465A-BFAC-F5F14CD2068DQ33807186-62D516F7-B976-44D0-A05D-4B8884BBEC8EQ33815631-C2425502-AEC2-47ED-B4F9-7D1322832129Q33857680-7D809853-A4D3-4C7C-812C-57083A3929C6Q33905411-AF66C3BD-0CDB-482E-8496-5D7359B231C6Q34072111-C87DB8DC-35E2-406C-B7D1-E5C70EA7B1F3Q34135089-EC29317F-C5D3-4C45-A187-44895E9C1472Q34255166-ED662464-0828-4E97-8245-8B6816EF06B0Q34649004-2476284B-EB0F-44D5-9CCA-193590CEFE54Q34662907-33B6F2F3-2663-418D-BFF0-142B1CCFC3CDQ34984972-5A5EE402-62E3-4D34-996F-4C3C923886A9Q35638378-4950589A-658F-45F7-978E-9081F9704C90Q35748144-DE280676-8590-4E1C-898D-3E8A569A99FCQ35750966-6CCA444E-476F-4C2A-A8BF-78B25ED3B143Q35772587-C00ED39B-0737-4F67-B61D-0597A8E65A84Q35809452-B55F0E2A-98BC-498C-AFF3-CAD5DF07345FQ35815967-8891DBAE-02D6-41BB-AAFD-F8BC70A158F5Q35828696-694FB540-D195-4244-9B54-BF714888426EQ35848361-594F56F1-53D3-415C-BF32-91541CA00A8DQ35848933-72692918-90FA-4546-8674-DF8771B916BAQ35874039-7E7FA9DE-961B-48A0-AC48-6F4CCF7F754FQ35970489-8250274D-7351-4445-945D-6032E605EC18Q36002331-4B89B1D4-180B-4FB1-B7A9-6BA638D0E569Q36133013-B53FCFBE-04E0-4469-B051-19E98CFD8605Q36326860-73F2648A-6ECD-49F4-8811-B2CC22F96B92Q36380188-BCE9AC96-5EB8-469B-BC84-8D2A54FC6FE5Q36471828-2FEBC4DE-167E-4244-98E1-E28F264AF9D8Q36522959-63156B8A-2FAE-447A-8F7A-9AF33D4C917CQ36777599-5F150C8E-2C65-4019-B294-AFD2BD27B9E3Q36940174-6F69B0E0-0357-42F6-9F9A-D406DEAA77DCQ36963137-9CE5F360-3E59-4FCE-B4AC-6450F096F69FQ37052632-68106527-19FA-4230-BBFC-792F0BA640A8Q37257446-3938FB28-9257-4322-8021-4929A5E5F129Q37358453-26EE6FD7-8695-4C6B-B9B6-4ADE44F8E28EQ37899200-1AD03D85-C056-47C1-B37A-7982369F7CA1Q38850104-6D14E3C5-66C4-4288-B030-1EA4F27B3EA9Q39996533-3A51C24D-B69E-4E7D-B545-B2DCEABD105FQ40354412-D239E4BB-F6EA-4B1B-AF06-125FD1515605Q40526136-077321C7-EB46-4359-B3A4-32579A62D602Q41146130-1D5FABEA-94B3-48E8-ADD3-C62236AF24F1
P2860
Chronic graft-versus-host disease: clinical manifestation and therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chronic graft-versus-host disease: clinical manifestation and therapy.
@ast
Chronic graft-versus-host disease: clinical manifestation and therapy.
@en
Chronic graft-versus-host disease: clinical manifestation and therapy.
@nl
type
label
Chronic graft-versus-host disease: clinical manifestation and therapy.
@ast
Chronic graft-versus-host disease: clinical manifestation and therapy.
@en
Chronic graft-versus-host disease: clinical manifestation and therapy.
@nl
prefLabel
Chronic graft-versus-host disease: clinical manifestation and therapy.
@ast
Chronic graft-versus-host disease: clinical manifestation and therapy.
@en
Chronic graft-versus-host disease: clinical manifestation and therapy.
@nl
P2093
P2860
P356
P1476
Chronic graft-versus-host disease: clinical manifestation and therapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BMT.1703111
P407
P577
2001-07-01T00:00:00Z
P5875
P6179
1005925265